<DOC>
	<DOCNO>NCT00028639</DOCNO>
	<brief_summary>RATIONALE : PS-341 may stop growth tumor cell block enzymes necessary cancer cell growth . PURPOSE : Phase II trial study effectiveness PS-341 treat woman metastatic breast cancer .</brief_summary>
	<brief_title>PS-341 Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective tumor response woman metastatic breast cancer treat bortezomib . - Determine toxic effect drug patient . - Determine progression-free survival patient treated drug . OUTLINE : Patients receive bortezomib IV 3-5 second twice weekly 2 week . Treatment repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 6-24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Previously treat 1 prior chemotherapy regimen ( without trastuzumab [ Herceptin ] ) metastatic disease Relapse within 6 month completion adjuvant chemotherapy consider treatment failure No known brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study No prior allergic reaction attribute compound similar chemical biological composition bortezomib No prior malignancy within past 5 year unless curatively treated disease free Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Prior hormonal therapy metastatic disease allow At least 4 week since prior hormonal therapy recover Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : Prior adjuvant therapy allow At least 4 week since prior investigational drug recover No concurrent investigational commercial agent therapy breast cancer No concurrent combination antiretroviral therapy HIV</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>